Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatl ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Panelists discuss common adverse events associated with subcutaneous nivolumab, emphasizing the importance of monitoring for immune-related adverse effects and managing them proactively to ensure ...

According to Zhen, the trial comparing nivolumab (Opdivo) plus chemotherapy vs chemotherapy alone led to an overall survival (OS) benefit in patients with a PD-L1 combined positive score (CPS) of 5 or ...

Rotating can help reduce pain when ongoing injections are needed. It may also reduce the risk of tissue scarring. Subcutaneous injections are those delivered in the fatty tissue that lies between the ...

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22, 2025. The FDA has accepted the biologics license application (BLA) for ...

The Dec. 27, 2024, Food and Drug Administration (FDA) approval of the subcutaneous injection formulation of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for patients with solid tumors opened up ...

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II drugs for Prostate Cancer have a 23% phase transition ...